Abeona Therapeutics Inc (ABEO) Short Interest Update

Abeona Therapeutics Inc (NASDAQ:ABEO) was the target of a significant increase in short interest in December. As of December 29th, there was short interest totalling 8,311,831 shares, an increase of 17.7% from the December 15th total of 7,058,902 shares. Based on an average daily volume of 633,976 shares, the short-interest ratio is presently 13.1 days. Currently, 27.3% of the company’s stock are short sold.

Abeona Therapeutics (NASDAQ ABEO) opened at $15.85 on Friday. Abeona Therapeutics has a 12-month low of $4.50 and a 12-month high of $22.75. The company has a market cap of $741.39, a PE ratio of -24.38 and a beta of 2.34.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05. Abeona Therapeutics had a negative net margin of 2,439.73% and a negative return on equity of 23.95%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million. equities analysts anticipate that Abeona Therapeutics will post -0.6 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Abeona Therapeutics by 11.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,081,670 shares of the biopharmaceutical company’s stock valued at $6,922,000 after acquiring an additional 108,730 shares during the period. State Street Corp bought a new position in shares of Abeona Therapeutics in the 2nd quarter valued at about $1,900,000. Northern Trust Corp grew its position in shares of Abeona Therapeutics by 406.3% in the 2nd quarter. Northern Trust Corp now owns 257,668 shares of the biopharmaceutical company’s stock valued at $1,649,000 after acquiring an additional 206,775 shares during the period. Point72 Asset Management L.P. bought a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $3,527,000. Finally, EAM Investors LLC bought a new position in shares of Abeona Therapeutics in the 3rd quarter valued at about $2,509,000. 41.95% of the stock is owned by institutional investors.

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald raised their target price on shares of Abeona Therapeutics from $21.00 to $34.00 and gave the company an “overweight” rating in a research report on Wednesday, October 11th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price (up previously from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 9th. Citigroup assumed coverage on shares of Abeona Therapeutics in a research report on Tuesday, October 10th. They issued a “buy” rating and a $32.00 target price for the company. ValuEngine downgraded shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Zacks Investment Research downgraded shares of Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $26.10.

COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics Inc (ABEO) Short Interest Update” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://stocknewstimes.com/2018/01/12/abeona-therapeutics-inc-abeo-short-interest-update.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply